Recent comments surrounding Establishment Labs Holdings (ESTA) have focused on its growing position in the US breast augmentation and reconstruction markets. In these markets, stronger demand expectations and supportive industry trends helped propel the share price.
Check out our latest analysis on Establishment Labs Holdings.
Those growth expectations can already be seen in the numbers, with the share price at $72.51 after a strong 90-day share price return of 85.21 percent and a five-year total shareholder return of 112.95 percent, suggesting momentum is clearly building rather than weakening.
If this type of healthcare growth story is on your radar, it’s worth exploring other potential opportunities using our healthcare stock screening program to see what else fits your strategy.
But with shares now trading near analyst targets after such a sharp run, the big question is whether Establishment Labs is still being mispriced by the market, or whether investors are already paying for tomorrow’s growth.
Most Popular Story: 2.3% Underrated
With Establishment Labs closing at $72.51 versus a narrative fair value near $74.22, the stock is framed as a modest discount despite its rally.
Improving operating leverage, through stable operating expenses, restraint in cash usage and expected EBITDA and cash flow milestones, is driving net margin expansion and earnings scalability as revenues continue to grow. Secular growth headwinds such as the rise of the global middle class and broadening social acceptance of aesthetic and reconstructive procedures are expected to drive higher procedure volumes worldwide, supporting multi-year revenue, margin and profit growth for Establishment Labs Holdings.
Read the full story.
Want to see what powers this top growth story? The narrative is based on rapidly building top lines, rapidly improving margins and a valuation multiple usually reserved for market darlings.
Result: Fair value $74.22 (UNDERVALUE)
Read the full narrative and understand what lies behind the predictions.
However, sustained high operating costs and a slower-than-expected commercial ramp-up in key markets could challenge both the pace and duration of the current growth narrative.
Learn about the key risks in this story from Establishment Labs Holdings.
Another view on valuation
Considered through multiple sales, Establishment Labs doesn’t look cheap. Shares trade at about 11 times sales versus about 3.5 times for the broader US medical equipment sector and 1.7 times for peers, above a fair 5.6 times ratio that could ultimately gravitate toward the market. That premium may reward the faithful if growth remains flawless, but how much margin of safety is really left if the story stumbles?
See what the numbers say about this price — find out in our valuation breakdown.
Build your own Labs Holdings Narrative
If you see the story differently or want to dig into the numbers yourself, you can quickly create a personalized view in minutes: Make it your way.
A great starting point for your research on Establishment Labs Holdings is our analysis that highlights 1 key reward and 1 major warning sign that could influence your investment decision.
Looking for more investment ideas?
Use the Simply Wall St Screener today to discover focused stock ideas across themes and sectors so you’re not left chasing the market later.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only an unbiased methodology and our articles are not intended as financial advice. It is not a recommendation to buy or sell stocks and does not take into account your goals or financial situation. Our goal is to provide you with long-term focused analysis based on fundamentals. Please note that our analysis may not take into account the latest company announcements that are price sensitive or quality material. Simply Wall St has no position in any of the listed stocks.
Valuation is complicated, but we’re here to make it simple.
Find out if Establishment Labs Holdings may be undervalued or overvalued with our detailed analysis, including fair value estimates, potential risks, dividends, insider trading and its financial condition.
Access to free analysis
Do you have comments on this article? Worried about the content? Contact us directly. Alternatively, email editorial-team@simplywallst.com
